BIOMARIN PHARMACEUTICAL HAS A RELATIVELY HIGH EV TO FORWARD EBITDA RATIO IN THE BIOTECHNOLOGY INDUSTRY (BMRN, CPHD, GHDX, ALXN, DNDN)

Below are the five companies in the Biotechnology industry with the highest Enterprise Value (EV) to Forward EBITDA ratios. EV/Forward EBITDA is an important metric used in valuing comparable companies and is based on estimated cash flow. It is capital structure neutral and generally the lower the ratio, the more undervalued the company is believed to be. BioMarin Pharmaceutical (NASDAQ:BMRN) has the highest with EV/Forward EBITDA of 39.03x; Cepheid (NASDAQ:CPHD) is next with EV/Forward EBITDA of 36.02x; and Genomic Health (NASDAQ:GHDX) has the next highest with EV/Forward EBITDA of 27.06x. Alexion Pharmaceuticals (NASDAQ:ALXN) follows with EV/Forward EBITDA of 25.24x and Dendreon (NASDAQ:DNDN) rounds out the group with EV/Forward EBITDA of 20.01x. SmarTrend currently has shares of Cepheid in an Uptrend and issued the Uptrend alert on September 03, 2010 at $17.38. The stock has risen 64.2% since the Uptrend alert was issued.

No comments:

Post a Comment

Superhit News

News Archive